Spyre Therapeutics, Inc. SYRE
Spyre Therapeutics, Inc. (Nasdaq: SYRE) is a GI/hepatology drug developer. Its lead program, SPY120 (α4β7 + TL1A combination), is in Phase 2 for Ulcerative Colitis. Its next catalyst on record is SKYLINE Part B (SPY120, SPY130, SPY230 combinations and monotherapies): Induction data (Q3 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SKYLINE Part B (SPY120, SPY130, SPY230 combinations and monotherapies) — Induction data (Q3 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SPY120 (anti-α4β7 + anti-TL1A combination) | Ulcerative Colitis | antibody | Phase 2 |
| SPY130 (anti-α4β7 + anti-IL-23 combination) | Ulcerative Colitis | antibody | Phase 2 |
| SPY230 (anti-TL1A + anti-IL-23 combination) | Ulcerative Colitis | antibody | Phase 2 |
| SPY001 (anti-α4β7) | IBD (UC/CD) | antibody | Phase 2 |
| SPY002 (anti-TL1A) | IBD (UC/CD) | antibody | Phase 2 |
| SPY003 (anti-IL-23) | IBD (UC/CD) | antibody | Phase 2 |
| SPY072 (anti-TL1A) | Hidradenitis Suppurativa | antibody | Phase 2 |
| SPY772 (anti-TL1A + anti-IL-17A/F combination) | Hidradenitis Suppurativa | antibody | Pre-clinical |
| SPY007 (anti-IL-17A/F) | Hidradenitis Suppurativa (combination component) | antibody | Pre-clinical |
Recent results and decisions
- Oct 31, 2026missed SPY072 was well-tolerated but did not meet its primary endpoint of ACR20 response in psoriatic arthritis.
The Company announced that SPY072 was well-tolerated, but neither sub-study met its primary endpoint of ACR20 response in PsA.
Filing - Sep 30, 2026met SPY003 achieved its primary endpoint in Part A of SKYLINE with a statistically significant 10.0 point reduction in RHI score.
SPY003 achieved their respective primary endpoints, demonstrating a statistically significant reduction in the Robart's Histopathology Index score of 10.0 points.
Filing - Sep 30, 2026started Spyre initiated SKYLIGHT Phase 2 trial of SPY072 in hidradenitis suppurativa subjects initiating bimekizumab.
In September 2026, the Company initiated its SKYLIGHT Phase 2 trial of SPY072 in subjects with moderately to severely active HS who are initiating bimekizumab.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.